Novavax, Inc. (NASDAQ:NVAX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

Recs

0
Player Avatar pchop123 (76.57) Submitted: 7/20/2012 3:08:54 PM : Underperform Start Price: $1.95 NVAX Score: -10.22

should repidly fall back to earth after an upside that could not be justified

Featured Broker Partners


Advertisement